Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies.

Folkert IW, Devalaraja S, Linette GP, Weber K, Haldar M.

J Bone Miner Res. 2019 Aug 23. doi: 10.1002/jbmr.3852. [Epub ahead of print]

PMID:
31441962
2.

Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.

Linette GP, Carreno BM.

Curr Hematol Malig Rep. 2019 Aug;14(4):286-291. doi: 10.1007/s11899-019-00523-x. Review.

PMID:
31187421
3.

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.

Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC.

Nat Med. 2019 Mar;25(3):454-461. doi: 10.1038/s41591-019-0357-y. Epub 2019 Feb 25.

4.

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.

D'Angelo SP, Hunger M, Brohl AS, Nghiem P, Bhatia S, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Schlichting M, Hennessy MH, Bharmal M.

Cancer Immunol Immunother. 2019 Apr;68(4):609-618. doi: 10.1007/s00262-018-02295-4. Epub 2019 Feb 5.

5.

RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.

Bagley SJ, Hwang WT, Brem S, Linette GP, O'Rourke DM, Desai AS.

J Neurooncol. 2019 Jan;141(1):95-102. doi: 10.1007/s11060-018-03010-0. Epub 2018 Oct 23.

PMID:
30353265
6.

Health-related quality of life in patients with malignant melanoma by stage and treatment status.

Rosenberg AR, Weston SJ, Deshields T, Fields RC, Linette GP, Cornelius LA, Semenov YR.

J Am Acad Dermatol. 2018 Jun 12. pii: S0190-9622(18)32068-1. doi: 10.1016/j.jaad.2018.06.007. [Epub ahead of print] No abstract available.

PMID:
29906543
7.

CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.

Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM.

Neuro Oncol. 2018 Oct 9;20(11):1429-1438. doi: 10.1093/neuonc/noy032.

PMID:
29509936
8.

Metastatic melanoma after solid organ transplantation: An interdisciplinary, institution-based review of management with systemic and targeted therapies.

Tripathi SV, Morris CR, Alhamad T, Fields RC, Linette GP, Cornelius LA.

J Am Acad Dermatol. 2018 Jan;78(1):184-185. doi: 10.1016/j.jaad.2017.06.031. No abstract available.

PMID:
29241778
9.

CAR T-Cell Therapies in Glioblastoma: A First Look.

Migliorini D, Dietrich PY, Stupp R, Linette GP, Posey AD Jr, June CH.

Clin Cancer Res. 2018 Feb 1;24(3):535-540. doi: 10.1158/1078-0432.CCR-17-2871. Epub 2017 Nov 20.

10.

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O.

Melanoma Res. 2017 Dec;27(6):585-590. doi: 10.1097/CMR.0000000000000398.

PMID:
29076950
11.

Neoantigen Vaccines Pass the Immunogenicity Test.

Linette GP, Carreno BM.

Trends Mol Med. 2017 Oct;23(10):869-871. doi: 10.1016/j.molmed.2017.08.007. Epub 2017 Aug 31.

12.

Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe.

Zhou Y, Tripathi SV, Rosman I, Ma J, Hai P, Linette GP, Council ML, Fields RC, Wang LV, Cornelius LA.

J Invest Dermatol. 2017 Jun;137(6):1370-1372. doi: 10.1016/j.jid.2017.01.016. Epub 2017 Feb 3. No abstract available.

13.

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.

Atkinson TM, Hay JL, Shoushtari A, Li Y, Paucar DJ, Smith SC, Kudchadkar RR, Doyle A, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Marr B, Abramson DH, Dickson MA, Schwartz GK, Carvajal RD.

J Cancer Res Clin Oncol. 2017 Mar;143(3):439-445. doi: 10.1007/s00432-016-2318-x. Epub 2016 Dec 5.

14.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA.

Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9.

15.

Management Controversies in Head and Neck Melanoma: A Systematic Review.

Zenga J, Nussenbaum B, Cornelius LA, Linette GP, Desai SC.

JAMA Facial Plast Surg. 2017 Jan 1;19(1):53-62. doi: 10.1001/jamafacial.2016.1038. Review.

PMID:
27606893
16.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P.

Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1.

17.

A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy.

Taylor SC, Hrisomalos F, Linette GP, Rao PK.

Am J Ophthalmol Case Rep. 2016 Apr 13;2:23-25. doi: 10.1016/j.ajoc.2016.04.004. eCollection 2016 Jul.

18.

Extensive tumoral melanosis associated with ipilimumab-treated melanoma.

Staser K, Chen D, Solus J, Rosman IS, Schaffer A, Cornelius L, Linette GP, Fields RC.

Br J Dermatol. 2016 Aug;175(2):391-3. doi: 10.1111/bjd.14474. Epub 2016 Mar 18.

PMID:
26877232
19.

pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens.

Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, Griffith M.

Genome Med. 2016 Jan 29;8(1):11. doi: 10.1186/s13073-016-0264-5.

20.

Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.

Alhamad T, Venkatachalam K, Linette GP, Brennan DC.

Am J Transplant. 2016 Apr;16(4):1332-3. doi: 10.1111/ajt.13711. Epub 2016 Mar 1. No abstract available.

21.

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Buchbinder EI, Sosman JA, Lawrence DP, McDermott DF, Ramaiya NH, Van den Abbeele AD, Linette GP, Giobbie-Hurder A, Hodi FS.

Cancer. 2015 Nov 15;121(22):4007-15. doi: 10.1002/cncr.29622. Epub 2015 Aug 11.

22.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS.

J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.

PMID:
26014293
23.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.

N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

24.

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, Linette GP.

Science. 2015 May 15;348(6236):803-8. doi: 10.1126/science.aaa3828. Epub 2015 Apr 2.

25.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
26.

Clonal architectures and driver mutations in metastatic melanomas.

Ding L, Kim M, Kanchi KL, Dees ND, Lu C, Griffith M, Fenstermacher D, Sung H, Miller CA, Goetz B, Wendl MC, Griffith O, Cornelius LA, Linette GP, McMichael JF, Sondak VK, Fields RC, Ley TJ, Mulé JJ, Wilson RK, Weber JS.

PLoS One. 2014 Nov 13;9(11):e111153. doi: 10.1371/journal.pone.0111153. eCollection 2014.

27.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK.

JAMA. 2014 Jun 18;311(23):2397-405. doi: 10.1001/jama.2014.6096.

28.

Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.

Sufficool KE, Hepper DM, Linette GP, Hurst EA, Lu D, Lind AC, Cornelius LA.

J Cutan Pathol. 2014 Jul;41(7):568-75. doi: 10.1111/cup.12346. Epub 2014 Apr 29.

PMID:
24641301
29.

Dendritic cell-based vaccines: Shining the spotlight on signal 3.

Linette GP, Carreno BM.

Oncoimmunology. 2013 Nov 1;2(11):e26512. Epub 2013 Oct 10.

30.

Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.

Lin AL, Liu J, Evans J, Leuthardt EC, Rich KM, Dacey RG, Dowling JL, Kim AH, Zipfel GJ, Grubb RL, Huang J, Robinson CG, Simpson JR, Linette GP, Chicoine MR, Tran DD.

Neuro Oncol. 2014 Jan;16(1):123-30. doi: 10.1093/neuonc/not142. Epub 2013 Nov 26.

31.

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK.

Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034.

32.

IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.

Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP.

J Clin Invest. 2013 Aug;123(8):3383-94. doi: 10.1172/JCI68395. Epub 2013 Jul 11.

33.

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH.

Blood. 2013 Aug 8;122(6):863-71. doi: 10.1182/blood-2013-03-490565. Epub 2013 Jun 14.

34.

Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib.

Kolar GR, Miller-Thomas MM, Schmidt RE, Simpson JR, Rich KM, Linette GP.

J Clin Oncol. 2013 Jan 20;31(3):e40-3. doi: 10.1200/JCO.2012.43.7061. Epub 2012 Dec 10. No abstract available.

PMID:
23233711
35.

Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.

Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K.

Mol Ther. 2012 Oct;20(10):1998-2003. doi: 10.1038/mt.2012.146. Epub 2012 Aug 7.

36.

Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells.

Carreno BM, Becker-Hapak M, Chan M, Lie WR, Wang X, Hansen TH, Linette GP.

J Immunol. 2012 Jun 15;188(12):5839-49. doi: 10.4049/jimmunol.1103647. Epub 2012 May 9.

37.

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O'Day SJ.

J Clin Oncol. 2012 Jan 1;30(1):34-41. doi: 10.1200/JCO.2011.34.6270. Epub 2011 Nov 28.

38.

Oligodendrogliomas in children.

Creach KM, Rubin JB, Leonard JR, Limbrick DD, Smyth MD, Dacey R, Rich KM, Dowling JL, Grubb RL Jr, Linette GP, King AA, Michalski JM, Park TS, Perry A, Simpson JR, Mansur DB.

J Neurooncol. 2012 Jan;106(2):377-82. doi: 10.1007/s11060-011-0674-6. Epub 2011 Aug 13.

PMID:
21842314
39.

Central nervous system cancers.

Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK Jr, Vrionis FD, Wen PY; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Apr;9(4):352-400. No abstract available.

PMID:
21464144
40.

Improved survival with ipilimumab in patients with metastatic melanoma.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.

N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

41.

Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.

Carreno BM, Garbow JR, Kolar GR, Jackson EN, Engelbach JA, Becker-Hapak M, Carayannopoulos LN, Piwnica-Worms D, Linette GP.

Clin Cancer Res. 2009 May 15;15(10):3277-86. doi: 10.1158/1078-0432.CCR-08-2502. Epub 2009 May 15.

42.

Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization.

Dayani PN, Gould JE, Brown DB, Sharma KV, Linette GP, Harbour JW.

Arch Ophthalmol. 2009 May;127(5):628-32. doi: 10.1001/archophthalmol.2009.45.

PMID:
19433711
43.

CD40 regulates human dendritic cell-derived IL-7 production that, in turn, contributes to CD8(+) T-cell antigen-specific expansion.

Carreno BM, Becker-Hapak M, Linette GP.

Immunol Cell Biol. 2009 Feb;87(2):167-77. doi: 10.1038/icb.2008.80. Epub 2008 Nov 11.

44.

Central nervous system cancers.

Brem SS, Bierman PJ, Black P, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Glass J, Grossman SA, Heimberger AB, Junck L, Linette GP, Loeffler JJ, Maor MH, Moots P, Mrugala M, Nabors LB, Newton HB, Olivi A, Portnow J, Prados M, Raizer JJ, Shrieve DC, Sills AK Jr.

J Natl Compr Canc Netw. 2008 May;6(5):456-504. No abstract available.

PMID:
18492461
45.

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E.

J Clin Oncol. 2008 May 1;26(13):2178-85. doi: 10.1200/JCO.2007.14.8288.

PMID:
18445842
46.

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.

Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE.

Cancer Chemother Pharmacol. 2009 Feb;63(3):451-8. doi: 10.1007/s00280-008-0756-0. Epub 2008 Apr 15.

PMID:
18414864
47.

Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides.

Truscott SM, Wang X, Lybarger L, Biddison WE, McBerry C, Martinko JM, Connolly JM, Linette GP, Fremont DH, Hansen TH, Carreno BM.

J Biol Chem. 2008 Mar 21;283(12):7480-90. doi: 10.1074/jbc.M709935200. Epub 2008 Jan 14.

48.

Hepatic arterial chemoembolization for management of metastatic melanoma.

Sharma KV, Gould JE, Harbour JW, Linette GP, Pilgram TK, Dayani PN, Brown DB.

AJR Am J Roentgenol. 2008 Jan;190(1):99-104.

PMID:
18094299
49.

Melanocyte receptors: clinical implications and therapeutic relevance.

Carlson JA, Linette GP, Aplin A, Ng B, Slominski A.

Dermatol Clin. 2007 Oct;25(4):541-57, viii-ix. Review.

50.

Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.

Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG.

Clin Cancer Res. 2005 Nov 1;11(21):7692-9.

Supplemental Content

Loading ...
Support Center